### Small Cell Lung Cancer Pre-HSCT Data

**Registry Use Only**

<table>
<thead>
<tr>
<th>Sequence Number:</th>
<th>Date Received:</th>
</tr>
</thead>
</table>

#### Disease Assessment at Diagnosis

1. What was the date of diagnosis of Small Cell Lung Cancer?  
   - Month: [ ]  
   - Day: [ ]  
   - Year: [ ]

2. What was the histology of the primary tumor at diagnosis?  
   - [ ] small lung cell cancer  
   - [ ] mixed small cell / non-small cell lung cancer  
   - [ ] other histology  
   3. Specify other histology: __________________________

Specify any diagnostic test(s) performed:

4. [ ] yes  [ ] no Biopsy  
5. [ ] yes  [ ] no Core needle biopsy  
6. [ ] yes  [ ] no Fine needle aspirate  
7. [ ] yes  [ ] no Sputum cytology  
8. [ ] yes  [ ] no Surgical resection  
9. [ ] yes  [ ] no Other test  
10. Specify other diagnostic test: __________________________

11. What was the location of the primary tumor at diagnosis?  
   - [ ] right lung  
   - [ ] left lung  
   - [ ] both lungs  
   - [ ] other site  
12. Specify primary tumor location: __________________________
13. What was the extent of the disease at diagnosis?

1. Limited — tumor(s) confined to one hemithorax and regional lymph nodes (including hilar, ipsilateral and contralateral mediastinal, and ipsilateral and contralateral supraclavicular lymph nodes) and ipsilateral pleural effusions (whether or not cytologically positive).

2. Extensive — any involvement which does not meet the definition of limited disease.

**TNM Stage at Diagnosis**

14. Specify the Tumor stage at diagnosis:

1. T0 — no evidence of primary tumor
2. TIS — carcinoma in situ
3. T1 — tumor ≤ 3 cm in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than lobar bronchi (i.e., the tumor does not invade the main bronchus, with the exception of superficially invasive tumor limited to the bronchial wall).
4. T2 — requires any of the following:
   - tumor > 3 cm
   - invades the mainstem bronchus but is no closer than 2 cm to the carina
   - invades the visceral pleura, or
   - is associated with atelectasis or obstructive pneumonitis that extends to the hilum but does not involve the entire lung
5. T3 — tumor of any size that invades the chest wall (including superior sulcus tumors), the diaphragm, the mediastinal or parietal pleura or the mainstem bronchus within 2 cm of the carina (but does not involve the carina); or tumor of any size that is associated with atelectasis or obstructive pneumonitis of the entire lung
6. T4 — tumor of any size that invades the mediastinum, heart, great vessels, trachea, esophagus, vertebral bodies or carina; or tumor that is associated with a malignant pleural effusion

15. Specify the Lymph Node stage at diagnosis:

1. N0 — no regional lymph node metastases present
2. N1 — ipsilateral peribronchial, hilar lymph nodes or both present, including direct extension
3. N2 — ipsilateral mediastinal, subcarinal lymph nodes or both present
4. N3 — contralateral mediastinal or hilar nodes or both; ipsilateral or contralateral scalene nodes, or supraclavicular lymph nodes present

Note: supraclavicular, scalene, paratracheal, peritracheal, paraesophageal, carinal, subcarinal, aortic, anterior and posterior mediastinal, hilar, intrapulmonic, and peribronchial lymph nodes are considered regional nodes.

16. Specify the Metastatic stage at diagnosis:

1. M0 — no distant metastases present
2. M1 — distant metastases present
CIBMTR Recipient ID: CIBMTR Center Number:

Specify any site(s) of disease at diagnosis (not including lung parenchyma):

17. 1 [ ] yes 2 [ ] no Adrenal glands
18. 1 [ ] yes 2 [ ] no Bone
19. 1 [ ] yes 2 [ ] no Bone marrow
20. 1 [ ] yes 2 [ ] no Brain parenchyma
21. 1 [ ] yes 2 [ ] no Cerebrospinal fluid (CSF)
22. 1 [ ] yes 2 [ ] no Liver
23. 1 [ ] yes 2 [ ] no Lymph nodes (confirm lymph node areas listed at question 15)
24. 1 [ ] yes 2 [ ] no Mediastinum
25. 1 [ ] yes 2 [ ] no Pericardium
26. 1 [ ] yes 2 [ ] no Pleura (includes pleural effusion)
27. 1 [ ] yes 2 [ ] no Skin / subcutaneous
28. 1 [ ] yes 2 [ ] no Mediastinoscopy
29. Specify other disease site:

Specify any disease staging test(s) performed at diagnosis:

30. 1 [ ] yes 2 [ ] no Abdomen computed tomography (CT) scan
31. 1 [ ] yes 2 [ ] no Bone marrow aspirate / biopsy
32. 1 [ ] yes 2 [ ] no Bone scan
33. 1 [ ] yes 2 [ ] no Bronchoscopy
34. 1 [ ] yes 2 [ ] no Chest CT scan
35. 1 [ ] yes 2 [ ] no Head CT or MRI
36. 1 [ ] yes 2 [ ] no Mediastinoscopy
37. 1 [ ] yes 2 [ ] no Thoracoscopy
38. 1 [ ] yes 2 [ ] no Thoracotomy
39. 1 [ ] yes 2 [ ] no Other test
40. Specify other staging test:

41. Enter age-appropriate Karnofsky or Lansky score at diagnosis:

(See complete scale on page 11 of Form 2000 — Recipient Baseline Data)

42. Did the recipient experience involuntary weight loss in the 6 months prior to diagnosis?

1 [ ] yes
2 [ ] no
3 [ ] unknown

43. Specify weight loss: % of total body weight

44. Does the recipient have a family history of lung cancer (among first- and second-degree relatives)?

1 [ ] yes
2 [ ] no
3 [ ] unknown

Laboratory Studies at Diagnosis

Report findings prior to any first treatment for small cell lung cancer.

45. LDH at diagnosis:

1 [ ] known
2 [ ] not known

46. Upper limit of normal for LDH:

47. Carcinoembryonic antigen (CEA) at diagnosis:

1 [ ] known
2 [ ] not known

Fax this form to your designated campus (Milwaukee 414-805-0714 or Minneapolis 612-627-5895).
Pre-HSCT Treatment for Small Cell Lung Cancer

48. Was therapy given between diagnosis and the start of the preparative regimen?

<table>
<thead>
<tr>
<th>Line of Therapy</th>
<th>1st Line of Therapy</th>
<th>2nd Line of Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date therapy started:</td>
<td>Date therapy stopped:</td>
<td></td>
</tr>
<tr>
<td>Systemic therapy:</td>
<td>Number of cycles:</td>
<td></td>
</tr>
<tr>
<td>carboplatin (Paraplatin)</td>
<td>51. yes 2 no cont. with q. 69</td>
<td></td>
</tr>
<tr>
<td>cisplatin (Platinol, CDDP)</td>
<td>unknown/not applicable</td>
<td></td>
</tr>
<tr>
<td>cyclophosphamide (Cytoxan)</td>
<td>53. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>docetaxel (Taxotere)</td>
<td>56. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>doxorubicin (Adriamycin)</td>
<td>57. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>etoposide (VP-16, VePesid)</td>
<td>58. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>gemcitabine (Gemzar)</td>
<td>59. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>ifosfamide (Ifex)</td>
<td>60. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>irinotecan (Camptosar)</td>
<td>61. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>paclitaxel (Taxol, Taxotere)</td>
<td>62. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>topotecan (Hycamtil)</td>
<td>63. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>vinblastine (VLB, Velban)</td>
<td>64. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>vincristine (VCR, Oncovin)</td>
<td>65. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>vinorelbine (Navelbine)</td>
<td>66. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>other chemotherapy</td>
<td>67. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>specify other chemotherapy</td>
<td>68. yes 2 no</td>
<td></td>
</tr>
<tr>
<td>Radiation Therapy:</td>
<td>69. yes 2 no cont. with q. 77</td>
<td></td>
</tr>
<tr>
<td>Central nervous system</td>
<td>70. yes 2 no cont. with q. 72</td>
<td></td>
</tr>
<tr>
<td>Specify total dose:</td>
<td>71. cGy (rads)</td>
<td></td>
</tr>
<tr>
<td>Thorax</td>
<td>72. yes 2 no cont. with q. 74</td>
<td></td>
</tr>
<tr>
<td>Other radiotherapy</td>
<td>73. cGy (rads)</td>
<td></td>
</tr>
<tr>
<td>Specify other radiation site:</td>
<td>74. yes 2 no cont. with q. 77</td>
<td></td>
</tr>
<tr>
<td>Specify total dose:</td>
<td>75. cGy (rads)</td>
<td></td>
</tr>
<tr>
<td>Surgery:</td>
<td>76. cGy (rads)</td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>77. yes 2 no cont. with q. 82</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>78. yes 2 no cont. with q. 82</td>
<td></td>
</tr>
<tr>
<td>other site</td>
<td>79. yes 2 no cont. with q. 82</td>
<td></td>
</tr>
<tr>
<td>specify other surgery site</td>
<td>80. yes 2 no cont. with q. 82</td>
<td></td>
</tr>
<tr>
<td>Was this line of therapy given for stem cell priming?</td>
<td>yes</td>
<td></td>
</tr>
</tbody>
</table>

Best Response to Line of Therapy:
(see definitions on page 6)

| Date response evaluated: |
| Did patient relapse/progression following this line of therapy? |
| Date of relapse/progression: |

Copy this page to report more than 2 lines of therapy; check here if additional pages are attached.
Most Recent Disease Assessment Prior to the Start of the Preparative Regimen

Indicate new sites of disease involvement at any time after diagnosis but before the start of the preparative regimen for HSCT:

If reporting a second or subsequent HSCT, list sites of disease involvement between last HSCT and prior to the current preparative regimen / HSCT.

125.  □ yes □ no Adrenal glands
126.  □ yes □ no Bone
127.  □ yes □ no Bone marrow
128.  □ yes □ no Brain parenchyma
129.  □ yes □ no Cerebrospinal fluid (CSF)
130.  □ yes □ no Liver
131.  □ yes □ no Lung (primary tumor)
132.  □ yes □ no Lymph nodes
133.  □ yes □ no Mediastinum
134.  □ yes □ no Pericardium
135.  □ yes □ no Pleura (includes pleural effusion)
136.  □ yes □ no Skin / subcutaneous
137.  □ yes □ no Other site

138. Specify other disease site: ________________________________

139. Was the disease sensitive to chemotherapy, radiotherapy, or both prior to the preparative regimen? (Response to last treatment regimen given ≤ 6 months prior to HSCT.) (see disease status definitions on page 6)

1 □ sensitive: ≥ 50% reduction in bidimensional diameter of all disease sites with no new sites of disease (CR, VGPR, PR)
2 □ resistant: < 50% reduction in diameter of all disease sites or development of new disease sites (NR / SD, PD)
3 □ untreated (or treated > 6 months prior to transplant)
4 □ not assessable
5 □ unknown

140. What was the disease status at the last evaluation prior to the preparative regimen? (see definitions on page 6)

1 □ no disease treatment given at any time
2 □ CR
3 □ VGPR
4 □ PR
5 □ NR / SD
6 □ PD
7 □ relapse from CR (untreated)
8 □ NA

Indicate any known site(s) of disease immediately prior to the preparative regimen:

141.  □ yes □ no Adrenal glands
142.  □ yes □ no Bone
143.  □ yes □ no Bone marrow
144.  □ yes □ no Brain parenchyma
145.  □ yes □ no Cerebrospinal fluid (CSF)
146.  □ yes □ no Liver
147.  □ yes □ no Lymph nodes
148.  □ yes □ no Mediastinum
149.  □ yes □ no Pericardium
150.  □ yes □ no Pleura (includes pleural effusion)
151.  □ yes □ no Primary tumor
152.  □ yes □ no Skin / subcutaneous
153.  □ yes □ no Other site

154. Specify other disease site: ________________________________

155. Date of the most recent assessment for disease status prior to the preparative regimen: ________________________________
**Small Cell Lung Cancer Disease Response / Status**

1. complete response (CR) – no tumor; no metastatic sites
2. very good partial response (VGPR) – primary tumor decreased by 90–99%; no metastatic sites; scar may be present, mediastinal nodes \( \leq 1.5 \) cm diameter; residual \(^{99}\)Tc bone changes allowed
3. partial response (PR) – primary tumor decreased by \( \geq 50\)%; all measurable metastatic sites decreased by \( > 50\)%
4. no response / stable disease (NR / SD) – no new lesions; < 50% reduction but < 25% increase in any existing lesion
5. progressive disease (PD) – any new lesion; increase of any measurable lesion by \( \geq 25\)%; previously negative bone marrow positive for tumor
6. not assessed (NA)